NCT07579507Not yet recruiting
Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 5 May 2026
- Start date
- Jun 2026
- Primary completion date
- Mar 2035
- Lead sponsor
- Centre Leon Berard
- Diseases
- Head and neck cancer
- NCT number
- NCT07579507
What you commit to
- Study type: Interventional
- Planned participants: 150
- From Jun 2026 to the primary completion date, Mar 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.
Other
- NI2: Pregnant or nursing woman.
- NI3: Contraindication to general anesthesia.
- NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
- NI5: Patient under curatorial or guardianship or placed under the protection of justice.
Who the study is looking for
- I1: Male or female at least 18 years old.
- I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.
- I3: Patient who has agreed to participate in this research and sign consent.
- I4: Patient affiliated to a medical insurance.
- I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.